Newsroom

The world is taking notice of Neuron23's breakthrough science. Take a look.

For Media Relations

If you're a member of the media or analyst community and would like to speak with the Neuron23 team, please get in touch with us.

Greig Communications

neuron23@greigcommunications.com 310-403-8951
Highlight

Neuron23™ Closes $113.5 Million Series A And B Financing Led By Westlake Village BioPartners, Kleiner Perkins, And Redmile Group

Read Full Story
News

In the News

  • NEWS /

    Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug

    Collaboration combines leading expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGEN’s long-standing experience in companion diagnostic development SOUTH SAN FRANCISCO, Calif. and GERMANTOWN, Md. and HILDEN, Germany, Sept. 14, 2022 /PRNewswire/ — Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological […]

    Read More
  • NEWS /

    Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer

    Longtime clinical development leader will help advance pipeline of precision medicines for genetically defined neurological and immunological diseases, with initial focus on Parkinson’s disease SOUTH SAN FRANCISCO, Calif., April 12, 2022 – Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment […]

    Read More
  • NEWS /

    Neuron23™ Closes $113.5 Million Series A And B Financing Led By Westlake Village BioPartners, Kleiner Perkins, And Redmile Group

    Biotechnology company launches to accelerate development of precision medicines for genetically defined neurological and immunological diseases

    Read More